Liontrust Investment Partners LLP Purchases 11,981 Shares of Omnicell, Inc. $OMCL

Key Points

• Liontrust Investment Partners LLP increased its stake in Omnicell, Inc. by 7.3%, owning a total of 175,655 shares valued at approximately $6.14 million.
• Omnicell's stock has a market capitalization of $1.45 billion and reported earnings of $0.45 per share, surpassing analysts' estimates.
• Analysts rate Omnicell as a "Moderate Buy" with a consensus target price of $46.71, despite recent adjustments to price targets from other investment firms.

Liontrust Investment Partners LLP increased its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 7.3% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 175,655 shares of the company's stock after buying an additional 11,981 shares during the period. Liontrust Investment Partners LLP owned 0.37% of Omnicell worth $6,141,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Victory Capital Management Inc. raised its position in shares of Omnicell by 10.1% during the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock worth $58,745,000 after purchasing an additional 154,038 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after acquiring an additional 394,820 shares in the last quarter. Lazard Asset Management LLC increased its position in shares of Omnicell by 81.6% during the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after purchasing an additional 737,536 shares during the last quarter. ArrowMark Colorado Holdings LLC raised its position in Omnicell by 4.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock worth $53,290,000 after acquiring an additional 56,117 shares in the last quarter. Finally, Toronto Dominion Bank bought a new stake in shares of Omnicell in the 4th quarter valued at about $30,637,000. Institutional investors own 97.70% of the company's stock.

Analyst Ratings Changes

Several analysts recently commented on OMCL shares. Wall Street Zen downgraded shares of Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Bank of America raised their price target on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Piper Sandler set a $55.00 price objective on shares of Omnicell and gave the company an "overweight" rating in a research report on Monday, August 11th. Wells Fargo & Company increased their target price on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a report on Monday, July 21st. Finally, Benchmark cut their price objective on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.08 on Monday, reaching $31.61. 485,100 shares of the company's stock were exchanged, compared to its average volume of 607,039. Omnicell, Inc. has a 52 week low of $22.66 and a 52 week high of $55.74. The firm has a market cap of $1.45 billion, a price-to-earnings ratio of 63.22, a P/E/G ratio of 9.25 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.42 and a quick ratio of 1.24. The stock has a fifty day simple moving average of $29.45 and a 200-day simple moving average of $32.07.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.30 by $0.15. Omnicell had a return on equity of 4.27% and a net margin of 2.01%. The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. During the same quarter last year, the business posted $0.51 earnings per share. The firm's revenue was up 5.0% compared to the same quarter last year. As a group, sell-side analysts predict that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.